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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 











a cohort study 
The Lancet 
Rheumatolog
y | Article 
• Some patients with 
C19 develop a C19-
associated 
hyperinflammatory 
syndrome that has 
similarities with other 
hyperinflammatory 
disorders 
• This study is the first 












score) by comparing 
published clinical 
data for C19 with 
clinical features of 
other 
hyperinflammatory 
or cytokine storm 
syndromes  
hyperinflammation 
• Though independent 
validation is needed, 
authors suggest that 
the cHIS scale may 
help define target 
patient populates for 





















• Data from the Indian states 
of Tamil Nadu and Andhra 
Pradesh show SARS-CoV-
2 transmission pathways 
and mortality in a high-
incidence setting 
• Reported cases and 
deaths have been 
concentrated in younger 
cohorts than expected from 
observations in HICs, even 
when taking into account 
for demographic 
differences across settings 
• Same-age contacts were 
associated with the 
greatest infection risk 
• Case-fatality ratios 
spanned 0.05% at ages 5-







25.09.2020 Report 33 – 
Modelling the 
allocation 
and impact of 
a COVID-19 
vaccine 
ICL | Report 
33 
• Efficacy and safety results 
of several SARS-CoV-2 
vaccine candidates now in 
late-stage trials are 
expected by the end of 
2020. Even under 
optimistic scenarios for 
manufacture and delivery, 
doses available in 2021 are 
likely to be limited 
• Optimal vaccine allocation 
strategies within and 
between countries are 




health (avert deaths) under 
constraints on dose supply 
• This report shows that as 
supply increases, vaccines 
that reduce or block 
infection (and therefore 
transmission) in addition to 
preventing disease have a 
greater impact that those 
that prevent disease alone, 
due to the indirect 
protection provided to high-
risk groups 
• The health impact of 
vaccination will depend on 
the cumulative infection 
incidence in the population 
when vaccination begins, 
the duration of any 
naturally acquired 
immunity, the likely 
trajectory of the epidemic 
in 2021 and the level of 
healthcare available to 
effectively treat those with 
disease 
• Within a country, for a 
limited supply (doses for 
<20% of the population), 
the optimal strategy is to 
target the elderly and high-
risk groups 
• However, for a larger 
supply, the optimal strategy 
switches to targeting key 
transmitters (i.e. the 
working age population 
and potentially children) to 
indirectly protect the elderly 
and vulnerable 
• A strategy in which doses 
are allocated to countries 
in proportion to their 
population size is close to 
optimal in averting deaths, 
given the likely global dose 
supply in 2021 (2 billion 







CGD | Policy 
paper 
• Using inputs generated 
from expert interviews, this 
modelling work suggests 
that here is a 50% chance 
that by the end of April 









of success of 
COVID-19 
vaccines 
vaccine safe and 
efficacious to gain 
regulatory approval; by the 
end of 2021 this rises to 
85% 
• This modelling also 
suggests that it will 
probably take more than a 
year to produce enough 
vaccines to inoculate the 
world’s 50 million medical 
staff and maybe Sept 2023 
before there are enough 
doses for the whole world 
• Experts predict that first-
generation vaccines will 
not be effective enough to 
fully prevent infection and 
end the pandemic 





















• In this study, data is 
collected from residents 
of informal settlements 
around Nairobi, Kenya 
to assess if control 
measures have 
changed contact 
patterns and the impact 
of changes on R0 is 
estimated 
• Kenyan government 
restrictions reduced 
social contacts with an 
estimate of R0 below 1 
but with a trade-off that 
86% report total or 
partial income losses 
and 74% reported 
eating less or skipping 
meals due to having too 
little money for food 
• Reductions is R0 are 
consistent with the 
comparatively low 
epidemic growth in 






early control measures, 
however, these 
measures may not be 
sustainable given the 
negative and inequitable 
impacts on economic 



























• Reliable point-of-care (POC) 
diagnostics not requiring 
laboratory infrastructure could 
be a game changer in the C19 
pandemic 
• This prospective, multi-centre 
diagnostic accuracy study in 
Germany and UK assessed the 
performance, limit of detection 
(LOD) and ease-of-use of 3 
antigen-detecting, rapid POC 
diagnostics for SARS-CoV-2 
• One test (SD Biosensor Inc. 
STANDARD Q) met the 
predefined target of >=98% 
specificity and was considered 
easy to use and suitable for 
POC and given usability at 
POC is likely to have impact 
despite imperfect sensitivity at 
86.6% (95% CI 62.8 to 86.4) 























insufficiency but this 





• Recent studies have 
indicated a worse 
prognosis for people 
with C19 who 
developed 
thromboembolism 
• Objective: to assess 




placebo or no 
intervention, on 
mortality and the 
need for respiratory 
support in people 
hospitalised with C19 
• Currently insufficient 
evidence to 
determine the risks 





• More robust 
evidence will be 
added to this review 
in future updates 
from 22 ongoing 
studies that plan to 
evaluate more than 
15,000 participants 
in hospital settings 
30.09.2020 Efficacy and 
safety of 
hydroxychloroq














• In this double-blind, 
placebo-controlled 
randomised clinical 
trial that included 
132 participants and 
was terminated 







and placebo cohorts 
• Among hospital-
based health care 
workers, 
hydroxychloroquine 





Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
05.10.2020 India’s new paper COVID-19 test could be a 
‘game changer’ 
BBC News 
03.10.2020 Leveraging the advances in HIV for COVID-
19 
The Lancet | Comment 
02.10.2020 Vaccine experts speak out on COVID-19 
vaccine and how to prepare  
CGD | Blog 
01.10.2020 When will we have a COVID-19 vaccine? 
Predictions, analysis and questions 
answered 
CGD | Blog 
01.10.2020 Leveraging the strengths of a mixed 
purchasing system for COVID-19: a 
perspective from Indonesia  
P4H | Blog 
01.10.2020 Symptoms of a broken system: the gender 
gaps in COVID-19 decision-making 
BMJ Global Health | 
Commentary 
30.09.2020 COVID-19 and African rheumatology: 
progress in adversity 
The Lancet Rheumatology | 
Comment 
28.09.2020 Providing essential TB services during 
COVID-19 
Health Policy and Planning | 
Blog 
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  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 





US NIH   Our World in 
Data: C19 
Testing 






Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
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19 pandemic  
Africa CDC Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 







  IDA 






















g in low 
resource 
settings 

























  Social 
Development 
Direct C19 blog 
series 














Institute of Public 
Health 
    
COVID-19 
Digest 





Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The 
Lancet 
 HEART     




 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    




    
Our World in 
Data 




  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  












      
WorldPop           
Flowminder           





    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 















Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours per 
week 




WHO Academy and 
WHO Info mobile 
applications 





















5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 











online brief with Dr 
David Nabarro 




























the Novel Coronavirus 
Online 
learning 




































of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
  
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
© Crown copyright 2020. 
 
